Coronavirus breakthrough as inhaled drug reduces risk of severe disease by 79%
INSUBCONTINENT EXCLUSIVE:
Synairgen, the firm behind the drug, has published the results from its clinical trial of the drug, dubbed SNG001, in hospitalised Covid-19
patientsThis article first appeared/also appeared in Mirror
